The nation of Zimbabwe has turned down a major US health deal worth $367m (272 million pounds) spanning five years because of the United States' request for sensitive information.
This move was revealed after a official document from December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
An official spokesperson has since stated that the US was seeking biological samples for research and commercial gain while was unwilling to guarantee the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable process of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished over $1.9bn in health funding to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged continued talks to find a deal acceptable to both sides so the nation's critical HIV programme can continue.
Wider Implications
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a high court suspended a related health funding agreement following concerns were filed about the security of citizens' health data.
After resuming office recently, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had managed assistance for the US government, but Trump argued its expenditure was "inefficient" and his administration was pursuing direct bilateral deals to enhance transparency and accountability.
According to statements, Sixteen nations in Africa have so far agreed to similar health pacts, representing over $18.3bn in new funding.
Specifics of the Rejected Agreement
The money for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration could have provided significant advantages for Zimbabwean communities, especially the 1.2 million currently receiving HIV treatment via US-supported programmes," Tremont said.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"Our nation was requested to provide its genetic material and health information for a long time, with no corresponding promise of benefiting from any scientific breakthroughs – such as new medicines or tests – that could be developed from that shared data," his statement read.
"Effectively, our country would provide the raw materials for scientific discovery without any certainty that the end products would be accessible to our people should a new health crisis emerge."
Sovereignty and Global Health
He also pointed out that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were disrupting systems previously set up through the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to manage potential pandemics.
"This framework is designed to guarantee that when a country contributes its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the capability to create them."
The government's concerns over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to ongoing dialogue with our American counterparts on how future co-operation might be arranged in a manner that honours the sovereignty and dignity of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the government's concerns, but urged that talks need to persist considering a large portion of the country's Aids initiatives relied on external financing.
"If specific concerns arise, such as those involving data governance or implementation frameworks, these can frequently be addressed through technical clarification and negotiated safeguards," it added.
The halted deal highlights the complex debate between accepting vital international aid and protecting local interests in an increasingly data-driven world.